Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

MERS-CoV RBD-mRNA Presents Better Immunogenicity and Protection than the Spike-mRNA

Cells(2025)10.3390/cells14231928Source: DataRank Database

MERS-CoV RBD-mRNA Presents Better Immunogenicity and Protection than the Spike-mRNA is a research paper published in Cells (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.00)OA: goldTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Abhishek Kumar Verma ORCID,Xiaoqing Guan ORCID,Shengnan Qian,Stanley Perlman ORCID,Lanying Du ORCID

Live enrichment

PubMed:41369417 PMC:PMC12691421 OpenAlex:https://openalex.org/W4416993877

National Institutes of Health

Grant: R01AI137472

National Institutes of Health

Grant: R01AI139092

NIH HHS

Grant: 5R01AI139092-06A0

NIH HHS

Grant: 5R01AI137472-06A0

FWCI

0.00

Citation Percentile

0.4%

goldLicense: cc-by

journalhttps://www.mdpi.com/2073-4409/14/23/1928/pdf?version=1764854435

publisherhttps://www.mdpi.com/2073-4409/14/23/1928/pdf?version=1764854435

publisherhttps://www.mdpi.com/2073-4409/14/23/1928/pdf

journalhttps://doi.org/10.3390/cells14231928

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41369417

Fields of Study

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesRespiratory viral infections researchMiddle East Respiratory Syndrome CoronavirusAnimalsSpike Glycoprotein, CoronavirusMiceRNA, MessengerAntibodies, NeutralizingCoronavirus InfectionsAntibodies, ViralHumansFemaleViral VaccinesMice, Inbred BALB CImmunogenicity, VaccineNanoparticles

MeSH Terms

Immunogenicity, VaccineAnimalsAntibodies, ViralFemaleHumansMice, Inbred BALB CRNA, MessengerViral VaccinesCoronavirus InfectionsMiceNanoparticlesAntibodies, NeutralizingSpike Glycoprotein, CoronavirusMiddle East Respiratory Syndrome Coronavirus

Keywords

ImmunogenicityNeutralizing antibodyAntibodyMiddle East respiratory syndromeImmune systemProtein subunitVaccine efficacyReceptorNeutralizing activityCoronavirusspikeProtective efficacyReceptor-binding domainMers-cov

MERS-CoV RBD-mRNA Presents Better Immunogenicity and Protection than the Spike-mRNA

FAIR Checklist

Authors (6)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)